Acute nonlymphocytic leukemia (AML)

Causes and Risks:
AML may occur at any age, but it primarily occurs in adults and in children below 1 year old. In acute leukemia , the malignant cell loses its ability to mature and specialize (differentiate) its function. These cells multiply rapidly and replace the normal cells. Bone marrow failure occurs as malignant cells replace normal bone marrow elements. The person becomes susceptible to bleeding and infection as the blood cells lose their ability to function.

Most cases seem to have no apparent cause. However, radiation, some toxins such as benzene, and some chemotherapy agents are thought to cause leukemia . Abnormalities in chromosomes may also play a role in the development of acute leukemia. Risk factors include exposure to radiation and chemicals, immunosuppression following organ transplantation, and blood disorders such as polycythemia vera , essential thrombocytopenia, and refractory anemia . The incidence is 1 out of 10,000 people.

Prevention:
Get protection from occupational exposure to agents associated with the development of acute leukemia and minimize radiation exposure.

Symptoms:



Signs and Tests:
A physical examination shows enlarged liver and spleen.

Children have bone and joint manifestations with areas of bone destruction and periosteal elevation by xray.

Treatment:
The objective of treatment is to eliminate the malignant cells with chemotherapy . This process also eliminates normal cells that may be present in the bone marrow. It takes several weeks for the bone marrow to recover and start producing normal cells. During this time supportive care is intensive. It consists of patient isolation to prevent infection, antibiotics to treat infection, transfusions of platelets to control bleeding , and red blood cell transfusions to combat anemia . Intensive chemotherapy, or chemotherapy in conjunction with bone marrow transplant , are potential curative treatments after remission has been achieved.

The FDA has recently approved a new drug called Vesanoid (all-trans retinoic acid) to treat promyelocytic leukemia , a rare but lethal form of AML leukemia. This drug works by causing the leukemic cells to rapidly age and die off, allowing the body to replace them with normal myelocytic cells. In preliminary clinical trials, this drug has resulted in a complete remission in half of the patients who failed standard treatment.

Support Groups:
The stress of illness can often be helped by joining a support group where members share common experiences and problems. See cancer - support group and leukemia - support group .

Prognosis:
Complete remission occurs in 70% to 80% of patients. Long-term survival achieved by curative therapy occurs in 20% to 30% of people. Without treatment, life expectancy is about 3 to 4 months.

Complications:

  • relapse of the disease
  • severe infection



Call Your Healthcare Provider:
Call for an appointment with your health care provider if symptoms suggestive of AML develop.

Call your health care provider if persistent fever or other signs of infection occur in a person with AML.


This microscope image shows AML cells (acute myeloblastic leukemia; also referred to as ANLL, acute nonlymphocytic leukemia). Certain internal cell structures are typical of AML. These include prominent nucleoli (red arrows) and cytoplasmic granules (grainy structures inside the cell which indicate some degree of cell maturation--black arrow).




This microscope image shows immature cells containing prominent nucleoli. The nuclei are large, lobulated, and/or irregular, resembling the nuclei of monocytes.